nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Assessment of Juvenile Pigs to Serve as Human Pediatric Surrogates for Preclinical Formulation Pharmacokinetic Testing
|
Roth, Wyatt J. |
|
2013 |
15 |
3 |
p. 763-774 |
artikel |
2 |
Bioequivalence for Locally Acting Nasal Spray and Nasal Aerosol Products: Standard Development and Generic Approval
|
Li, Bing V. |
|
2013 |
15 |
3 |
p. 875-883 |
artikel |
3 |
CDER Risk Assessment Exercise to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products
|
Cruz, Celia N. |
|
2013 |
15 |
3 |
p. 623-628 |
artikel |
4 |
Clinical Pharmacokinetics of Buffered Propranolol Sublingual Tablet (Promptol™)—Application of a New “Physiologically Based” Model to Assess Absorption and Disposition
|
Wang, Yanfeng |
|
2013 |
15 |
3 |
p. 787-796 |
artikel |
5 |
Comparative In Silico–In Vivo Evaluation of ASGP-R Ligands for Hepatic Targeting of Curcumin Gantrez Nanoparticles
|
D’Souza, Anisha A. |
|
2013 |
15 |
3 |
p. 696-706 |
artikel |
6 |
Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia
|
Fetterly, Gerald J. |
|
2013 |
15 |
3 |
p. 662-673 |
artikel |
7 |
Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective
|
Prueksaritanont, Thomayant |
|
2013 |
15 |
3 |
p. 629-645 |
artikel |
8 |
Effect of Censoring Due to Progressive Disease on Tumor Size Kinetic Parameter Estimates
|
Bonate, Peter L. |
|
2013 |
15 |
3 |
p. 832-839 |
artikel |
9 |
Engineered Mannitol Ternary Additives Improve Dispersion of Lactose–Salbutamol Sulphate Dry Powder Inhalations
|
Kaialy, Waseem |
|
2013 |
15 |
3 |
p. 728-743 |
artikel |
10 |
Epigenetic Modifications of Nrf2 by 3,3′-diindolylmethane In Vitro in TRAMP C1 Cell Line and In Vivo TRAMP Prostate Tumors
|
Wu, Tien-Yuan |
|
2013 |
15 |
3 |
p. 864-874 |
artikel |
11 |
Evaluation of Pre-existing Antibody Presence as a Risk Factor for Posttreatment Anti-drug Antibody Induction: Analysis of Human Clinical Study Data for Multiple Biotherapeutics
|
Xue, Li |
|
2013 |
15 |
3 |
p. 893-896 |
artikel |
12 |
Factors Influencing Magnitude and Duration of Target Inhibition Following Antibody Therapy: Implications in Drug Discovery and Development
|
Chimalakonda, Anjaneya P. |
|
2013 |
15 |
3 |
p. 717-727 |
artikel |
13 |
Generic Development of Topical Dermatologic Products, Part II: Quality by Design for Topical Semisolid Products
|
Chang, Rong-Kun |
|
2013 |
15 |
3 |
p. 674-683 |
artikel |
14 |
Impact of Anti-Drug Antibodies in Preclinical Pharmacokinetic Assessment
|
Thway, Theingi M. |
|
2013 |
15 |
3 |
p. 856-863 |
artikel |
15 |
Mathematical Model Approach to Describe Tumour Response in Mice After Vaccine Administration and its Applicability to Immune-Stimulatory Cytokine-Based Strategies
|
Parra-Guillen, Zinnia P. |
|
2013 |
15 |
3 |
p. 797-807 |
artikel |
16 |
Molecular Mechanisms of Silibinin-Mediated Cancer Chemoprevention with Major Emphasis on Prostate Cancer
|
Ting, Harold |
|
2013 |
15 |
3 |
p. 707-716 |
artikel |
17 |
Non-Arrhenius Protein Aggregation
|
Wang, Wei |
|
2013 |
15 |
3 |
p. 840-851 |
artikel |
18 |
Nonlinear Absorption Kinetics of Self-Emulsifying Drug Delivery Systems (SEDDS) Containing Tocotrienols as Lipophilic Molecules: In Vivo and In Vitro Studies
|
Alqahtani, Saeed |
|
2013 |
15 |
3 |
p. 684-695 |
artikel |
19 |
Predictive Models of Diffusive Nanoparticle Transport in 3-Dimensional Tumor Cell Spheroids
|
Gao, Yue |
|
2013 |
15 |
3 |
p. 816-831 |
artikel |
20 |
Pre-Existing Biotherapeutic-Reactive Antibodies: Survey Results Within the American Association of Pharmaceutical Scientists
|
Xue, Li |
|
2013 |
15 |
3 |
p. 852-855 |
artikel |
21 |
Protective Effects of Kaempferol on Isoniazid- and Rifampicin-Induced Hepatotoxicity
|
Shih, Tung-Yuan |
|
2013 |
15 |
3 |
p. 753-762 |
artikel |
22 |
Resveratrol Suppresses T0901317-Induced Hepatic Fat Accumulation in Mice
|
Gao, Mingming |
|
2013 |
15 |
3 |
p. 744-752 |
artikel |
23 |
Risk Assessment of Drug Interaction Potential and Concomitant Dosing Pattern on Targeted Toxicities in Pediatric Cancer Patients
|
Barrett, Jeffrey S. |
|
2013 |
15 |
3 |
p. 775-786 |
artikel |
24 |
Sequential Bioequivalence Trial Designs with Increased Power and Controlled Type I Error Rates
|
Fuglsang, Anders |
|
2013 |
15 |
3 |
p. 659-661 |
artikel |
25 |
Theoretical Considerations and Practical Approaches to Address the Effect of Anti-drug Antibody (ADA) on Quantification of Biotherapeutics in Circulation
|
Kelley, Marian |
|
2013 |
15 |
3 |
p. 646-658 |
artikel |
26 |
Utilization of Gene Expression Signature for Quality Control of Traditional Chinese Medicine Formula Si-Wu-Tang
|
Xie, Chen |
|
2013 |
15 |
3 |
p. 884-892 |
artikel |
27 |
What is the Likelihood of an Active Compound to Be Promiscuous? Systematic Assessment of Compound Promiscuity on the Basis of PubChem Confirmatory Bioassay Data
|
Hu, Ye |
|
2013 |
15 |
3 |
p. 808-815 |
artikel |